Amphetamine Induced Adult Respiratory Distress Syndrome

Sponsor
Arrowhead Regional Medical Center (Other)
Overall Status
Completed
CT.gov ID
NCT05611385
Collaborator
(none)
49
1
12
4.1

Study Details

Study Description

Brief Summary

Methamphetamine and amphetamine has various cardiovascular and central nervous system effects. Long-term use is associated with many adverse health effects including cardiomyopathy, hemorrhagic, and ischemic stroke. Death is usually caused by cardiovascular collapse and while amphetamine abuse has been considered as a potential cause of acute respiratory distress syndrome, the reports are usually anecdotal. This investigation considers reviewing individuals with few to zero medical conditions who develop acute respiratory distress syndrome and are methamphetamine positive

Condition or Disease Intervention/Treatment Phase
  • Other: Difference in development of Acute Lung Injury in Amphetamine positive and negative patients

Detailed Description

Methamphetamine and amphetamine has various cardiovascular and central nervous system effects. Initially prescribed in the 1930s for respiratory ailments such as asthma, current clinical indications of amphetamine range from treatment of attention deficit hyperactivity disorder to narcolepsy. The mechanism of action is primarily potentiation of release of monoamine neurotransmitters, mainly dopamine and norepinephrine, from presynaptic nerve endings into the synaptic space, in addition to attenuation of monoamine metabolism by inhibiting monoamine oxidase. This in turn leads to an increase in sympathetic tone by alpha and beta adrenergic receptor activation, resulting in elevations in heart rate, respiratory rate, and vascular tone. Long-term use is associated with many adverse health effects including cardiomyopathy, hemorrhagic and ischemic stroke. Other long-term associations include increased violent behavior, documented increased motor vehicle accidents, and clandestine manufacturing of the drug.

Methamphetamine has also been associated with deleterious effects on society as a whole; it is credited as a cause of increase in rates of crime, abuse, and unemployment, and associated with great economic burden. A significant portion of healthcare resources consumed are rooted in the emergency department, particularly in trauma. Studies previously performed have demonstrated that methamphetamine use among patients that present to trauma centers has been continually increasing. Death is usually caused by cardiovascular collapse and while amphetamine abuse has been considered as a potential cause of acute respiratory distress syndrome, the reports are usually anecdotal. This investigation considers reviewing individuals with few to zero medical conditions who develop acute respiratory distress syndrome and are methamphetamine positive

Study Design

Study Type:
Observational
Actual Enrollment :
49 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
High Incidence of Adult Respiratory Distress Syndrome Associated With Amphetamine Use in the Burn Population
Actual Study Start Date :
Jan 1, 2019
Actual Primary Completion Date :
Jan 1, 2020
Actual Study Completion Date :
Jan 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Positive for Amphetamine

Patients admitted to the burn unit that are positive for amphetamine

Other: Difference in development of Acute Lung Injury in Amphetamine positive and negative patients
No Intervention

Negative for Amphetamine

Patients admitted to the burn unit that are negative for amphetamine

Other: Difference in development of Acute Lung Injury in Amphetamine positive and negative patients
No Intervention

Outcome Measures

Primary Outcome Measures

  1. Inhalation Injury [24 hours]

    Documentation on admission of inhalation injury as defined by burned nasal hairs, burned facial skin, and carbonaceous sputum after admission to the hospital within the first 24 hours.

  2. Total Burn Surface Area [24 hours]

    The total burn surface area of the patient on arrival to the hospital assessed within the first 24 hours. With respect to the total burn surface area recorded only 2nd degree burns will be considered as defined as burns that affect the epidermis and dermis.

  3. Length of hospital stay [180 days]

    The total length of hospitalization of individuals with burns and acute respiratory distress syndrome with a max of 180 days from admission.

  4. Stroke Volume [Collected in the first 5 days after admission]

    Measurement of cardiovascular parameter (stroke volume) of patients with acute respiratory distress syndrome and total burn surface area between 20%-60% in the first 5 days of admission to the hospital.

  5. Cardiac Output [Collected in the first 5 days after admission]

    Measurement of cardiovascular parameter (cardiac output) of patients with acute respiratory distress syndrome and total burn surface area between 20%-60% in the first 5 days of admission to the hospital.

  6. Central Venous Pressure [Collected in the first 5 days after admission]

    Measurement of cardiovascular parameter (central venous pressure) of patients with acute respiratory distress syndrome and total burn surface area between 20%-60% in the first 5 days of admission to the hospital.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Total body surface area burns between 20% and 60% admitted to the burn unit
Exclusion Criteria:
  • Under 18 years of age

  • Burns outside of the inclusion ratio

Contacts and Locations

Locations

Site City State Country Postal Code
1 Arrowhead Regional Medical Center Colton California United States 92324

Sponsors and Collaborators

  • Arrowhead Regional Medical Center

Investigators

  • Study Chair: Aldin Malkoc, MD, Arrowhead Regional Medical Center
  • Principal Investigator: David T Wong, MD, Arrowhead Regional Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Arrowhead Regional Medical Center
ClinicalTrials.gov Identifier:
NCT05611385
Other Study ID Numbers:
  • 15-24
First Posted:
Nov 10, 2022
Last Update Posted:
Nov 10, 2022
Last Verified:
Nov 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 10, 2022